XTend Medical Corp. – XMDC.pk
XTend Medical Corporation (XMDC) Finalizes Asset Purchase With BioHarp, Korea
SUN VALLEY, CA--(Marketwire - 12/09/09) - XTend Medical, (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, today announced the company has completed and signed the asset purchase agreement with BioHarp, Korea.
The company released the following statement, "Mr. Lee, Mr. Friedman, and I are pleased to announce the completion of the asset purchase agreement between XTend Medical and BioHarp, Korea. The process took a little longer than anticipated but we're extremely excited to finalize this agreement and work together with Mr. Lee to begin the manufacturing, marketing, and sales of the BioHarp device. XTend Medical has an incredible asset that will insure the company's valuation moving forward. The device will, in our opinion, be known very soon as the premier medical diagnostic tool worldwide. We're thoroughly impressed with the team behind the BioHarp and are looking forward to a long lasting relationship. XTend Medical will move quickly to gain sales in Korea, China, Japan, and other countries that have expressed interest in the unit and to have a combined operation so our reach is global in nature. We anticipate the sales of the BioHarp to reach phenomenal numbers in the coming years," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
Mr. Lee, CEO of BioHarp, Korea, added, "I am extremely excited about the future of the BioHarp. Our team, combined with the management of XTend Medical, will insure the company's success. We look forward to working closely with Mr. Lisenby and Mr. Friedman as we begin the manufacturing and sales process globally and deploy the BioHarp to health organizations throughout the world."
XTend Medical Corporation (XMDC) Discusses Corporate Structure
SUN VALLEY, CA--(Marketwire - 11/19/09) - XTend Medical (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following statement regarding their corporate structure:
"We've had several email inquiries as to the company's corporate structure regarding the press release issued on November 18th in regards to the upcoming asset purchase and merger with BioHarp. Our current authorized share structure will not change in order to effectuate this transaction. Our current capital reserves are also sufficient to consummate the asset purchase. We have began the process of converting preferred shares into common shares in order to insure the integrity of the company as we move forward to gain a listing on a higher exchange. There will be no need to alter our authorized shares whatsoever. In addition, the potential of the company in the future would justify us maintaining our current share structure with no plans to reverse the stock. Mr. Friedman and I feel strongly enough about the BioHarp that we will be utilizing our equity in the company to finalize any shares issued for the transaction. As for any delays perceived, it is my responsibility as CEO of XTend to insure the company has taken the proper steps to insure our valuation is at the greatest and we adhere to all U.S. and international tax laws and regulations. The company will finalize any merger opportunities, now and in the future, in the proper manner so as to insure the future of the company is not placed in harms way," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
XTend Medical Corporation (XMDC) Moves Forward on Merger With BioHarp Korea
SUN VALLEY, CA and SEOUL, KOREA--(Marketwire - 11/18/09) - XTend Medical, (Pinksheets:XMDC -News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, today announced the company is in the final stages of completing the merger between XTend Medical Corporation and BioHarp, Korea.
The company issued the following statement: "We're proud to announce XTend has finished their meetings in Korea with BioHarp. While we originally intended to just merge operations, XTend feels it will be in the best interest to purchase the assets wherein the newly merged entity would own the BioHarp medical device in its entirety. This insures the company has sufficient assets for proper company valuation as we look to begin the process of moving to a higher exchange. As this will involve both securities and cash, it is imperative to properly investigate any tax implications or other fees that may have an affect on both companies to insure the company is following proper procedures for the regulatory agencies. We will consult with our corporate counsel and CPA to insure we protect the company and complete this with the proper documentation and approvals. Mr. Lee will be traveling to Los Angeles at the beginning of December to meet with us to discuss the operational aspects of the new entity as we move forward," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
XTend Medical Corporation (XMDC) Retains Carl Duncan, Esq., to Handle Company's Legal Strategy and Affairs
SUN VALLEY, CA--(Marketwire - 11/03/09) - XTend Medical Corporation (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, announced today the company has retained Mr. Carl Duncan, Esq., to become corporate counsel and to handle the filings necessary for the company to migrate to the OTC Bulletin Board trading market.
"We're extremely pleased that Mr. Duncan has agreed to serve as our independent corporate counsel and securities attorney to handle all of our legal strategies and affairs. He will also be handling all the filings necessary for XTend Medical to apply for a listing on the OTC Bulletin Board trading markets upon completion of our company's audited financials. Mr. Duncan has over 37 years' experience in corporate securities law and has represented more than 350 issuers in as many as 48 states concurrently and in an aggregate of 15 countries. Our continued work with Mr. Duncan will spearhead our proposed upcoming listing to the Bulletin Board will be done in accordance with all securities laws and his knowledge in international securities will also serve XTend well as we seek listings, in due course, on other capital markets globally," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
XTend Medical (XMDC) Updates Shareholders on Merger and Company's Progress
SUN VALLEY, CA--(Marketwire - 10/22/09) - XTend Medical (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the company's progress on merger and company's progress:
"XTend would like to update our shareholders on our progress to date. Mr. Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with the executives of XTend. The meetings were very positive and included several aspects in the manufacturing process and the business model moving forward. I personally want to thank Mr. Lee for his dedication and efforts in moving the merger forward. The management of XTend will be traveling to Korea soon to meet with the executives of BioHarp, Korea to finalize the merger. We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company. While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company.
The combined efforts of the seasoned technical team in Korea with the management in the U.S. will insure that the BioHarp device will become the standard in medical diagnosis. Our intention is to market the product aggressively throughout Asia, the U.S. and Europe. To date, we've had over 7 inquiries from medical device companies looking to represent the BioHarp in 4 different countries globally. As we move forward, these opportunities will be explored and if they benefit the company, we will press forward on a working relationship.
As to the BioHarp unit itself, I would like to reiterate a few areas that make this device unique:
1. The BioHarp requires a pre-scan of the patient in order to get a baseline reading. This baseline reading is not based solely on a set of standards in the medical sector. These individualized baselines are established from the patient's own cellular makeup and further solidify how the BioHarp sets itself apart from any present of future competitors.
2. The BioHarp device is completely portable. Unlike CT Scanners and other large pieces of equipment that remain stationary, the BioHarp can travel to where the patients are. The unit is perfect for rural areas, battlefields, or other outlying areas that would benefit by having the BioHarp as part of their healthcare service.
3. BioHarp can be used to detect cellular inflammation in plants. Diseases in crops have risen dramatically over the years and the BioHarp can assist scientists in helping to determine the proper course of treatment in order to insure plants can sustain life. The global percussion in this area can be tremendous for the company.
4. The dedication Mr. Lee has spent on this device over the past 14 years is truly incredible. His vision for this device has proven instrumental in the development of the BioHarp. His technical staff has, and continues t, spend countless hours perfecting this product and we feel honored to become part of this exciting and truly unique product.
In closing, I would like to thank all of our shareholders for being patient as we close this merger. Mr. Lee and I have worked continuously over the past two years to insure you, as shareholders, will reap the benefits of being part of something we're very proud of. The future is very bright for this company and through hard work and dedication, the BioHarp will flourish and become the leading diagnostic device in the global medical community," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
XTend Medical (XMDC) Discusses BioHarp Market Potential and Revenue Model
SUN VALLEY, CA--(Marketwire - 10/12/09) - XTend Medical (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the BioHarp market potential:
"As the company moves closer to completing the merger with BioHarp Korea, the management feels it is vital for our shareholders to understand the market potential and the revenue model of the BioHarp device. The BioHarp unit market potential stretches globally. There has been interest from several health departments globally to deploy the BioHarp to outlying village areas and major metropolitan healthcare clinics to utilize the BioHarp as an effective tool for pre-diagnosis on regular physical appointments. Since the BioHarp can travel anywhere with a laptop, the ability for these countries to deploy the unit to hard to get geographical areas allows these countries to scan the patient and choose the correct follow-up procedures that can save these countries millions of dollars in healthcare costs. These countries will use the five sensor unit and the software will be integrated into their respective national healthcare databases.
"In addition to the human markets, the BioHarp will be marketed to the pet and equine industries. The management at XTend has made several contacts with the veterinary market to utilize the BioHarp to scan dogs, cats, and other pets in order to discover potential harmful conditions that can be treated through nutrition and medications. The ability for the veterinarian to market this as an added service allows them to create an additional revenue stream as well as giving pet owners the ability to monitor their pet's health and hopefully alleviate costly procedures. The equine industry itself can be very lucrative for the company in the future. The management at XTend has several thoroughbred trainers and owners they have spoken with about utilizing the BioHarp as part of a daily routine for racehorses to insure their training and subsequent earnings potential is not compromised. As the BioHarp unit can be deployed to the stables, part of their post exercise routine would be for the trainer or vet to scan the horse upon completion of their workout or race and determine if there is any underlying inflammation that can lead to being sidelined, thereby eliminating the ability to earn money racing. This market alone is global in nature as there are literally hundreds of racetracks with thousands of horses, each representing a significant investment to their owners. The yearling sales at places like Keenland, wherein owners plunk down millions to own a potential Triple Crown winner, would benefit by having a BioHarp scanner available in order to scan potential champions to insure the fitness of the horse and to detect potential problems that could arise in the future. These scans would be done with the one sensor unit and would probably be sold and managed by our internal medical team at BioHarp UNI US. The potential trainers and owners would contract with us to scan the animals regularly; generating daily, weekly, and/or a monthly maintenance fee schedule for the company.
"The revenue model for the BioHarp comes from both the hardware and software sales. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. Naturally, if we have groups that are purchasing thousands of units, we will have a discount structure to these monthly fees. With the patient potential in the millions, our revenue model will be very strong and consistent for years to come.
"Lastly I would like to touch on our corporate structure and how we feel the share structure will be beneficial for all current and future shareholders of the company. We strongly feel that our Authorized shares at this time are sufficient to handle our merger and capital raise needs. We feel it would be disadvantageous to do any sort of reverse split due to the potential sales of the BioHarp unit in the coming years. If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we've received, the company's market cap will be substantial," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
Letter to Shareholders of XTend Medical (XMDC) From the CEO Regarding the Upcoming Merger With BioHarp, Korea
SUN VALLEY, CA--(Marketwire - 10/06/09) - XTend Medical (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following letter from the CEO, Mr. Paul D. Lisenby, regarding the upcoming merger with BioHarp, Korea and other corporate progress.
"To all XTend shareholders, I want to bring everyone up to date on the upcoming merger with BioHarp, Korea, and to share some insight into the future of the company. As you are aware from our most recent press release, we've decided to merge our company with BioHarp, Korea in order to have one of the most intriguing and cutting-edge medical devices to hit the healthcare industry in decades. The potential for this device to change the way patient diagnostics are currently being done is tremendous. The BioHarp is a non-invasive scanning device that can be used by a trained professional to scan the body to find cellular inflammation, utilizing nano bio-sensors. In layman's terms, whenever there is inflammation in the body on a cellular level, the potential for health issues can result. The BioHarp is a patent protected device that doesn't require any dyes or foreign fluid to be introduced into the body to attain a reading, or better yet, gives the patient results based on their individual body baseline. In short, this device can be used as an early diagnostic device by any country, healthcare company, managed care company, military, and in almost any other situation where an early diagnosis can assist in saving lives and lowering healthcare costs.
The work done by our management team with the principles at BioHarp, Korea, has taken us over two years to get to this point in our relationship wherein we feel comfortable merging with their organization and they feel the same way with us. Our hard work over the past three years in dealing with managed care companies, physician groups, and other healthcare organizations will prove to be most beneficial in securing future contracts for the BioHarp once the merger is complete. BioHarp, Korea has spent the last 14 years working on bringing the BioHarp unit to its current level of perfection and by combining our resources we gain solid management, premiere manufacturing, and the potential for a global company that will make BioHarp the most used medical device in early diagnosis.
There was a press release in February 2008, issued by Hathaway Corporation, announcing a joint venture with UNI Bio-Tech for the BioHarp device. As I was with the company at that time acting as the interim CEO, I knew the value of BioHarp. However, since the Board of Directors of Hathaway decided to change their business model to become FutureWorld Energy and focus their efforts on the renewable energy sector, the joint venture never took place and the deal was cancelled in April of 2008. My work with Hathaway has since stopped and for the last 18 months my sole responsibility has been to ensure XTend Medical brings value to our shareholders and puts itself in a position to capitalize on opportunities to grow the company. Through this merger, the company will become a global leader in the healthcare sector and it will be up to all of us here at XTend Medical and BioHarp, Korea to ensure that this happens.
Since the announcement of this merger, we have been working hard with Pink Sheets to become fully compliant with their reporting requirements. We should have this accomplished by week's end and hopefully have the Stop Sign removed from our company's profile. Our goal is to move up to a greater exchange due to the potential sales that we anticipate the BioHarp will be doing globally very soon. We are working with our accountant and legal teams to ensure that we have everything in order so the migration to a higher exchange can be accomplished at the proper time. Any changes we've recently made to the corporate structure are to effectuate this merger and any and all shares issued for this merger are subject to Rule 144 Restrictions. As we update Pink Sheets, the information will be there for all shareholders to review. We are in the process of updating our site and will share additional information about our progress in future press releases. In closing, I would like to thank all of our loyal shareholders for their dedication and for potential future shareholders; this company will be strong and have a very bright future for many years to come."
XTend Medical (XMDC) Signs Letter of Intent to Merge With BioHarp, Korea
SUN VALLEY, CA--(Marketwire - 10/01/09) - XTend Medical, (Pinksheets:XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, announced today the company has signed a Letter of Intent to Merge with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device. Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number. The share structure of the company will remain in effect with no changes anticipated.
BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body's organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases. This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.
Unlike CT Scans, MRIs and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in increasing morbidity rates and lowering health costs significantly.
The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.
"The management at XTend has been working diligently on this merger for the past 9 months to insure we create a powerful opportunity for the company to have a clear manufacturing partner, cutting-edge medical device, and the market whereby we can sell this device globally to healthcare organizations and countries looking to detect early signs of diseases that will save lives and lessen costs associated with treating these diseases," stated Mr. Paul Lisenby, CEO of XTend Medical. Mr. Lisenby further states, "The BioHarp has gone through several revisions and is now ready to go into full production. The device is not only intended for humans, but the application has shown that animals can benefit from this technology as well. Our goal is to get this device into the hands of physicians, veterinarians, and other professionals that understand the technology can detect, on a molecular level, inflammation that can lead to serious health problems. We will market this product aggressively and have already been contacted by several countries in Asia and Europe that are interested in making the BioHarp part of their national healthcare program. We're very excited to work closely with the doctors and scientists associated with the BioHarp unit in Korea to continue to upgrade the unit for potential use by the general public. We expect to finalize this merger in the next thirty to sixty days."
The company is currently updating their website. www.xtendmedical.com.
XTend Medical (XMDC) Updates Shareholders on Company's Progress
SUN VALLEY, CA, Sept. 29 /PRNewswire-FirstCall/ - XTend Medical, (Pinksheets: XMDC - News), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following statement:
"The company has been repositioned over the last 8 months to capitalize on the expanding global health markets for telemedicine and telehealth devices that can deliver results in order for health organizations, managed care companies, physician groups, and evolving third-world countries to increase their ability to diagnose health conditions that can lead to costly treatments. We have been approached by several global companies to become partners and/or merge with their companies in order to capitalize on our past experiences in dealing with major healthcare organizations. As these potential candidates have expressed their desire to become part of XTend Medical, we will quickly move to strengthen the company and position ourselves as global leader in the telehealth and telemedicine solutions. As the company progresses on these matters, we will keep our shareholders abreast of our progress. We feel very strongly that the hard work we've done over the past 2 years has allowed us to be known globally as a company that can deliver defined solutions to the healthcare market. XTend Medical will focus on the most elite products and companies thereby creating tremendous shareholder value."
The company is currently updating their website. www.xtendmedical.com
Bioharp DD:
Pictures of Bioharp
BioHarp Trade Show Booth Photo's from KIMES
BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body’s organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases.
This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.
The unit itself combines with state-of-the-art software developed specifically to assimilate and deliver the results from the 1 or 5-sensor “wand” that scans the body and sends the data for review by a licensed physician, physician’s assistant, or registered nurse for possible further testing or to define the proper course of treatment.
Unlike CT Scans, MRI’s and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in increasing morbidity rates and lowering health costs significantly.
The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.
The BIOHARP is an easy-to-use device intended as a self-examination tool, It is a handheld device no bigger than a cell phone making it a convenient and portable. The device is also available in industrial size, which can detect infectious diseases in the body through a non-invasive, non- restrictive method , through the external scan of the whole body.
The BIOHARP will be used as a preventative method against catastrophic diseases by assisting in early diagnosis. In a 5-minute scan with BIOHARP, the user can pinpoint areas of cellular inflammation. The BIOHARP introduces a revolutionary method for diagnosis.. The BIOHARP measures the biological and pathological signals at the cellular level. This signal can be correlated to cellular inflammation when compared to healthy cellular activity in the body.
Cellular inflammation is a key indicator for malfunction and can be used to assist in the diagnosis of diseases. It is not suggested that the BIOHARP be used as a replacement for existing technologies but rather as a precursor to limit and suggest targeted tests, providing the patient with effective healthcare and a better overall experience.
SOFTWARE
The software used in the BioHarp device is a Windows based, 3D imaging program that directs the users to specific points in the body for examination. As you can see from the following slides, this software pinpoints the readings from the BioHarp and gives the physician or tech a full reading for further treatment of the areas scanned.
The software incorporates the details needed for the proper sales functions to major healthcare companies. By requesting specific patient data as well as any corresponding medical record numbers, the integration into the databases for internal EHR (Electronic Health Records) that current healthcare companies are embracing for patient care.
Frequently Asked Questions:
Q: If I were to go to my doctor or physician, how do they determine my baseline readings? Is it in the same visit?
A: The same day. It takes about 2-3 minutes to establish your baseline readings and then the actual scan can be done in as little as 10-15 minutes.
Q: How is the baseline established for the proper reading of the BioHarp:
A: The process is started by "wanding" the body with the hand held unit. The data is then sent to the software and a "Baseline" cellular reading is established by the software program. This is a very simple process and very user friendly.
Q: Have there been any human trials?
A: Yes, the BioHarp has been tested on humans and further testing will continue.
Q: Will the company be submitting the BioHarp to the US FDA?
A: This will be done in accordance with the KFDA so as to speed up the process of approval.
Q: Will you be submitting the BioHarp to other countries FDA's or other agencies you plan to sell the BioHarp into?
A: Yes, we will always comply with the requirements of the country we will be selling the BioHarp to.
Q: Do you need approval to sell the BioHarp to horticulture or vetrinary markets?
A: Currently there are no restictions in these sectors and the BioHarp will be marketed and sold to these areas in the immediate future.
UPDATED DECEMBER 10, 2009
Q: Will the company be raising the Outstanding Shares past the 1,000,000,000?
A: No, definitely no. We have the proper structure for the company now and in our future move to a higher exchange.
Q: Will the company be doing a reverse split?
A: No, definitely no. With the anticipated sales we will have there is no need to explore that whatsoever. We've had so many inquiries to date from several countries expressing interest in purchasing the BioHarp that our share structure will support the aniticpated revenues.
Q: When will the company begin to see sales of the BioHarp?
A: We are working right now on getting the final production unit done and ready to go. We expect to sell the BioHarp to veterinarians, equine, and horticulture markets in the first quarter of 2010. We are not limited to KFDA, CE, or FDA approval to do this.
Q: Why didn't you just do a simple merger rather than an asset purchase?
A: For valuation. A merge would not have given us the proper valuation for the company's anticipated move to a higher exchange. By purchasing the asset, XTend now has a measureable value for the future audit of the company. This will be very important when we file the forms to move to a higher exchange.
Q: Does the company has sufficient cash reserves to execute the business plan?
A: Yes! We are ready to execute the plan we have worked so hard to establish.
Q: When will the website be updated?
A: As we just finished up the asset purchase, we ask for a little patience from our shareholders. We're working on many items and the website is one of them. Look for a more robust website within the next 30 days wherein we will also have video demonstrations of the BioHarp
Screen Shots from Bioharp Computer readouts
August 15-17, 2007, BioHarp makes debut at FIME 2007
The world's medical marketplace, in Miami Beach convention center. Over 150 attendees, including 32 certified MD's from across the world, were scanned and diagnosed with BioHarp. The product demonstration included a 5 minutes scan of the major organs. In every case, where the volunteer had knowledge of their own medical history, we were able to confirm BioHarp's readings with 100% success. In other cases, we may identified potential problem areas, the volunteer should have checked out. There was a great deal of buzz at the UnI-Biotech booth, with several attendees returning with their co-workers, friends, and partners.
http://www.bioharpunius.com/
Sam Lee's Korean name from Trademark info: LEE, Sang-Moon
Patent App #20090182218
http://www.faqs.org/patents/app/20090182218
Written description of BioHarp From patent app.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42609252
Clinical test data...
A total of 656 measurements were carried out for three weeks using this method, on mice including those whose subcutaneous tissue was transplanted with cancer cells. In the initial seven (7) days after the transplantation, correct were 166 out of 190 measurements (87.4%), in which normal, healthy mice were not diagnosed with cancer. The total results were 629 hits out of 656 measurements (95.9%) in the experiment period, in which normal, healthy mice were not diagnosed with cancer. It can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer.
In another experimental example of the invention, the diagnostic device of the invention was used to diagnose cancer in the mice whose abdominal cavity was transplanted with leukemia cells. As a result, 84.7% were diagnosed with cancer in a control group, and the remaining 15.3% were diagnosed with inflammation instead of cancer. In the mice whose abdominal cavity was transplanted with leukemia cells, 93.1% were diagnosed with cancer. In view of the fact that cancer will not be induced in the control group but the group transplanted with cancer has a high probability of cancer, it can be appreciated that the diagnostic device of the invention has excellent sensitivity to biological electro-magnetic signals caused by cancer.
XMDC BioHarp Patent Images:
Very solid new management team for BioHarp Uni
Sam Lee
Mr. Lee is the brainchild behind the BioHarp unit. Mr. Lee has spent the past 14 years perfecting the nano bio-sensor technology and has worked diligently in the continued development of the sensor units and overall BioHarp product. Mr. Lee holds a BA in Public Administration and has a MA in Animal Physiology and Biochemistry.
Achievement
Established ‘ UNI BIO-TECH.,INC. ’, Seoul Korea. Jun 19. 2000.
Established R&D Biological Signal Technology, Calif. U.S.A. Mar 1989.
- R&D Biological Signals
- Analysing Study of the Characteristics of revolutionary Bio-Substances
- Unigue prosessing of Bio-Materials for Nano-Biosensor
- Nano- Biosensor development and Production for Hand-Held Detector.
- R & D of Immune strengthening, Prevention and Treatment of Cancer & related Diseases.
- Ubiquitous, e-Healthcare, Monitoring System
Development of Early stage disease detector using Nano-Biosensor
Detection of Biological Signals Non-Invasive, Non-Restrictive Diagnostic method
New Model Development of prototype, Sep 2008 ~ Jun 2009
KIMES 2008 participated in International Medical Convention at Seoul Korea, Mar 15. ~ Mar 17. 2008
FIME 2007 participated in International Medical Convention at Miami U.S.A, Aug 15. ~ Aug 17. 2007
Development of Biological signals detection device- BIOHARP-Hand held device, Jan 2007 ~ Aug 2007
KGLP approved laboratory animal pre-clinical experiment For new device which detects of early stage various diseases,
Apr 2004 ~ May 2004
Development of Prototype : Biological signals device of single Sensor and Multi-Sensor’s, Apr 2002 ~ May 2004
Dr. Hyung Geun Lim – CFO
Ph. D. : Business Administration
- World Trade Center Association(WTCA),
Deputy Coordinator of Asia Pacific Region, 1999~present
- Ph.D. in Business Administration
University of Southern California(U.S.C)
Graduate School of Business Administration, California, USA 1981~1987
- M.S. in Finance California State University at Los Angeles
Graduate School of Business Administration, California, USA, 1970~1972
- Professor of Won Kwang University, 1988~2007
- National Council for the president of Korea,
Regional Balanced Development Planning Committee, 2000~2002
- Visiting Professor of UCLA, 1991~1992
- Member of Korea Real Estate Policy Association, 2004~present
- Member of Korea Business Administration Association, 1994~present
- Member of Korea Financial Management Association, 1993~present
- Member of Daehan Business Administration Association, 1996~present
- Auditor of Advanced Korea Development Foundation 2008~present
- Founding President of Korea Town Rotary Club -L.A ,1988~1990
- President of Wilshire Center Community Involvement Association -L.A, 1987~1989
- Business Counselor in Financial Management, 1997~present
- State of Calif. Department of Real Estate,, Real Estate Broker License(Realtor), 1975~present
Technical Staff
Dr. B. Shtrupp
-M.D. Medical Doctor (Surgeon), Neuropathologist PhD; Scientist
Development of
- Structure of the Biosensor and functions
- Solution for the evaluation of the human physical state according to
Nano-BioSensor change through the Biological Signals
- Application of a high Biological signals measuring system to the cells for reactional Signals
- Symptoms and reaction of the Nano-Biosensor according to change in
internal organs
- Diagnostic of human disease according to the various Biological Signals Etc.
Dr. Ho Kwon Kim
Ph. D. : Mechanical Engineering
Professor of KAIST (Korean Advanced Institute of Science and Technology ) since 2004
Technology Policy Advisor of ADD (Agency for Defense Development) 2004
Vice president of ADD, Nov 2001 ~ Nov 2004
Director, 1st R & D Center of ADD, Mar 1995 ~ Feb 2000
Science & Technology Assistant for former Minister of M.N.D, Nov 1992 ~ Apr 1993
Head, Technology Department of ADD, Feb 1992 ~ Oct 1992
R & D Attache, ROK Embassy in Washington ,D.C U.S.A, Dec 1987 ~ Jun 1991
Chief , Technology project Group of ADD, Oct 1983 ~ Mar 1985
Catholic University U.S.A, Sep 1978 ~ Sep 1983
Article
Unified Analytical Kinematic Analysis and Synthesis of Spatial Mechanisms
Dr. Dong Myung Ahn
Ph. D. : Electronic Engineering
CEO, Genohco.,Inc
Visiting professor of Dongguk University since 2003
Head, electronic & communication division in ADD (Agency for Defense Development)
Ph.D. in Electrical Engineering, Polytechnic University in New york, 1991
M.S. in System Engineering, Polytechnic University in New york, 1986
M.S. in Electric Engineering, Seoul National University in Seoul, 1979
B.S. in Electronic Engineering, Sogang University, 1977
many papers, awards & patent holders in the area of electronic engineering
Member of the Korea Information & Communication Society
Dr. Tae Sam Yu
Ph. D. : Electronic Engineering
Chairman, Genohco.,Inc
President, Polytechnic University Alumni Association Korea Chapter
President, Korea Scientist and Engineer’s Association NY Metro Chapter
Member of Technical Staff, AT&T Bell Laboratory in USA from 1986 to 1995
CEO, Samwoo Telecommunication Industry in Korea from 1995 to 2004
Research engineer, Korea Institute of Science & Technology
Ph.D. in Electrical Engineering, Polytechnic University in New york, 1986
M.S. in Electrical Engineering, Polytechnic University in New york, 1983
B.S. in Electronic Engineering, Sogang University, 1974
Dr. Sung Jong Kim
Ph. D. : Electrical Engineering
Managing Director, Satellite Communication Department of KT Corporation in Korea from 1991 to 2006
Power Electronics Center from 1985 to 1990
Member of the Korea Society of Space Technology & APSCC
Ph.D. in Electrical Engineering, Virginia Tech, 1991
M.S. in Electrical Engineering, Virginia Tech, 1986
B.S. in Electrical Engineering, Seoul National University, 1976
Researcher, Satellite Power System Sector of Virginia
Researcher, missile division in ADD (Agency for defense Development)
Dr. Sung Ho Lim
Ph. D. : Electronic Engineering
Ph.D. in Electronic Engineering, Chungnam National University, 1999
M.S. in Electronic Engineering, Chungnam National University, 1995
B.S. in Electronic Engineering, Korea Aerospace University, 1984
Senior engineer, electronic & communication division in ADD (Agency for defense evelopment)
CEO, New-tech information & Communication Professional Engineers in Korea from 2002 to 2006
many papers, awards & patent holders in the area of electronic engineering
Dr. Jung Guk Kim
Ph. D. : Biomedical Electronics
1999. 03 ~ Present Professor of Myung-Ji University
1994. 08 ~ 1999. 02 Guidant Corp. ST Paul, Senior Research Scientist
1994. 04 ~ 1994. 06 University of Illinois at Chicago, Postdoc
1986. 04 ~ 1993. 12 University of Illinois at Chicago Bioengineering Program TA & RA
1985. 09 ~ 1993. 12 University of Illinois at Chicago Bioengineering Program
1984. 04 ~ 1985. 12 Beam Telecommunication, Inc. R & D Engineer
Article
• Automatic sensing level adjustment for implantable cardiac rhythm management devices.
• Automatic threshold sensitivity adjustment for cardiac rhythm management devices.
• Automatic sensing level adjustment for implantable cardiac rhythm devices
BioHarp - Genohco Connection
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44462334
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44462334
BioHarp - Victek Connection
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44435765
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44461881
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44462104
Company Info
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=xmdc
XMDC T&S
http://quotes.freerealtime.com/dl/frt/S?IM=quotes&SA=quotes%7CTime%2526Sales&symbol=xmdc&type=Time%26Sales&action=Go%21
XMDC B/S Trades
http://ih.advfn.com/p.php?pid=trades&cb=1216680156&symbol=PINK%5EXMDC
AS info DE. Dept. of Corp.
24/7 Phone: 302-739-3073, press #8 file number 3866564
http://www.corp.delaware.gov/default.shtml
Note: Web site does not give the AS. Must call, automated 24/7, or during business hours if one wishes to speak in person.
XTend Medical Corporation
10771 Sherman Way
Sun Valley, CA 91352
P:(818) 255-2476
F:(818) 255-2479
General Inquiries
info@xtendmedical.com
Managed Care Sales Pharmacy
mcsales@xtendmedical.com pharmacy@xtendmedical.com
Investor Relations
info@bioharpunius.com
Company Officers
Paul D. Lisenby, CEO, Chairman
Ben Friedman, President
Company Information
XTend Medical Corp.
10771 Sherman Way
Sun Valley, CA91352
http://www.bioharpunius.com
Transfer Agent
Signature Stock Transfer, Inc.
2632 Coachlight Ct.
Plano, TX75093
Phone972-612-4120 Fax972-612-4122
Email - signaturestocktransfer@msn.com
Share Structure
Outstanding Shares
As of 6/18/08: 28,437,031 shares outstanding; 21,403,469 shares free trading; 7,033,562 shares restricted
As of 7/01/08: 28,437,031 shares outstanding; 21,403,469 shares free trading; 7,033,562 shares restricted.
As of 7/03/08: 28,437,031 shares outstanding; 21,403,469 shares free trading; 7,033,562 shares restricted
As of 7/14/08: 28,437,031 shares outstanding; 21,403,469 shares free trading; 7,033,562 shares restricted
As of 7/16/08: 31,237,031 shares outstanding; 24,203,809 shares free trading; 7,033,562 shares restricted
As of 7/23/08: 36,737,031 shares outstanding; 30,057,796 shares free trading; 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 8/06/08: 36,737,031 shares outstanding; 30,057,796 shares free trading; 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 8/13/08: 36,737,031 shares outstanding; 30,057,796 shares free trading; 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 8/22/08: 86,737,031 shares outstanding; 80,057,796 shares free trading; 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 8/25/08: 101,737,031 shares outstanding; 95,057,796 shares free trading; 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 9/2/08: 245,737,031 shares outstanding; 239,489.809 shares free trading; 6,247,222 shares restricted; 1,000,000,000 shares Authorized.
As of 7/21/09: 256,737,031 shares outstanding; 239,065,599 shares free trading; 17,671,432 shares restricted; 1,000,000,000 shares authorized.
As of 9/22/09: 256,737,031 shares outstanding; 239,065,599 shares free trading; 17,671,432 shares restricted; 1,000,000,000 shares authorized.
As of 10/05/09: 616,737,031 shares outstanding; 299,065,600 shares free trading; 317,671,431 shares restricted; 1,000,000,000 shares authorized.
As of 10/27/09: 636,737,031 shares outstanding; 319,497611 shares free trading; 1,000,000,000 shares authorized.
As of 11/04/09: 649,737,031 shares outstanding; 332065,600 shares free trading; 1,000,000,000 shares authorized.
As of 11/09/09 766,487,031 shares outstanding ; 351,681,600 shares free trading and 414,805,431 restricted with 1,000,000,000 shares auth
As of 11/18/2009 770,487,031 shares outstanding 355,681,600 shares free trading and 414,805,431 restricted with 1,000,000,000 shares auth
As of 12/03/2009 783,137,031 shares outstanding with 370,891,600 shares free trading and 412,245,431 restricted with 1,000,000,000 shares authorized.
12-10-2009 was 986,490,863 shares outstanding with 378,391,600 shares free trading and 608,099,263 restricted with 1,000,000,000 shares authorized.
This board is for discussing XMDC.
Information posted either positive or negative is accepted.
Personal attacks, repetitive, off topic posts or outright flame baiting posts are not accepted.
Posts that respond to PM (One way messages) are not allowed. Vulgarity is not acceptable. Violation of ones privacy is not acceptable.
Posts in violation of the rules will be deleted. Repeat offenders will be reported to the admins of IHUB.
Rules of the board per IHUB:
http://www.investorshub.com/boards/complex_terms.asp
